These results are consistent with previous studies indicating that pan-HDAC inhibitors, such as TSA and SAHA, can downregulate both mRNA and protein levels of ERα, thereby inhibiting the growth of ER-positive breast cancer cells like MCF7 and T47D cells [25–27]. Here, ESR1 is linked to breast carcinoma.